Estepan Ian Michael, Chief Financial Officer of Sarepta Therapeutics (SRPT), has demonstrated a clear selling bias in his recent insider transactions, with $3.28 million in total sales compared to just $291,739 in purchases across 38 reported trades. His activity has been exclusively concentrated in SRPT shares, with no transactions in other companies. The most significant sales occurred in early 2025, including a $943,047 disposition on March 7, 2025, followed by additional sales totaling $289,375 and $105,236 on March 10, 2025. More recently, between February and March 2026, Michael executed a series of smaller sales, including transactions of $73,773 and $28,365 on February 26, 2026, and multiple sales in early March ranging from $9,881 to $53,476.
Notably, Michael’s buying activity was limited to early 2025, with his last recorded purchase occurring on January 29, 2025, valued at $307,053. Since then, his filings have reflected only sales or non-monetary transactions such as awards or option exercises. The absence of any recent acquisitions, combined with consistent disposals, suggests a sustained reduction in his SRPT holdings. The transactions, particularly the larger early 2025 sales, may indicate portfolio rebalancing or liquidity needs, though the filings provide no explicit rationale. The pattern underscores a shift from accumulation to distribution over the past year.
AI-assisted summary